USFDA Inspection at Indore Facility Ends with Zero Observations: Cipla
Drug firm Cipla Friday said the US health regulator conducted a post-approval inspection at its Indore facility, and it ended with zero observations.
New Delhi, May 17 (PTI) Drug firm Cipla Friday said the US health regulator conducted a post-approval inspection at its Indore facility, and it ended with zero observations.
"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations," the company said in a BSE filing.
Shares of Cipla closed at Rs 543.95 apiece on the BSE, down 1.2 per cent from its previous close. PTI
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)